



Barclays Global Healthcare Conference


March 11, 2021

BioCryst Pharmaceuticals

Jon Stonehouse, **CEO**

Forward- Looking Statements


BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at ir.biocryst.com/financial-information/sec-filings

A man with grey hair and a mustache, wearing blue-rimmed glasses and a blue and white striped shirt, is looking at a computer monitor. The monitor displays a complex 3D molecular structure with blue and red components. The background is dark, and there are several white dots in the top right corner.

Delivering extraordinary Empowering ordinary

BioCryst develops novel oral medicines designed to treat rare disease to help patients experience a normal quality of life.

BioCryst's Robust Pipeline



Orladeyo™ Launched

Orladeyo™
(berotralstat) capsules 150 mg



- **Strong early demand from patients for ORLADEYO**
 - Clinical trial conversions and patients new to ORLADEYO
 - New patients switching from all injectable prophylactics and acute therapy
 - Expanding prescriber base beyond investigators
- **Getting patients on therapy quickly while we secure reimbursement over time**

Significant Upcoming Milestones in 2021

 Q1 2021

 Q2 2021

 Q3 2021

 Q4 2021

 **Approval** decision on ORLADEYO in Japan (January 2021)

Data from completed BCX9930 dose ranging study in PNH (R&D Day: March 22)

Approval decision on ORLADEYO in EU

Revenues reported from Q1/first full quarter of ORLADEYO sales in US

Launch of ORLADEYO in Japan

Launch of ORLADEYO in Germany

 BCX9930 Advanced Development Trials

 BCX9250 Next Steps

 ORLADEYO REVENUES

Cash position (in millions) and 2021 Financial Outlook




Cash, cash equivalents, restricted cash & investments at December 31, 2019	\$138
Cash, cash equivalents, restricted cash & investments at December 31, 2020 ^A	\$303
Senior credit facility ^B	\$125

A – Reflects net cash received in December 2020 from Royalty Pharma and Athyrium Capital Management following transaction-related fees and payoff of prior MidCap debt

B - From Athyrium Capital Management, \$125M interest-only for 5-year term

In the launch period for ORLADEYO, the company is not providing specific revenue or operating expense guidance. Based on our expectations for revenue, operating expenses, and our option to access an additional \$75 million from our existing credit facility, we believe our current cash runway takes us into 2023.



PNH
9930



C3G
9930



ANCA
Vasculitis
9930



Lupus
nephritis
9930

9930
PIPELINE
IN A
MOLECULE



IgAN
9930



aHUS
9930



IgAN
vasculitis
9930



PMN
9930

Q1 Data Readout and Next Steps for BCX9930

Phase 1 dose-ranging trial in PNH has fully enrolled

- Data from total of 16 patients
- Duration of treatment up to >48 weeks
- Both treatment-naïve patients (n=10) and C5 inadequate responders (n=6)
- Data from 15 patients treated at doses of 400 mg bid or 500 mg bid for at least eight weeks
- Data to be announced at R&D Day on March 22nd
 - Plan to report range of clinical and laboratory outcomes, biomarkers and safety data

Next Steps

- Begin (2H 2021) pivotal trials in PNH patients at selected dose level
- Begin (2H 2021) PoC trial(s) in patients with renal complement-mediated diseases at same selected dose

Goal in PNH: BCX9930 as oral monotherapy for all PNH patients



Barclays Global Healthcare Conference

March 11, 2021

BioCryst Pharmaceuticals

Jon Stonehouse, **CEO**